K Ohgaki

620 citations
55 papers · 502 indexed · h-index 10

K Ohgaki

51 papers receiving 485 citations

Peers

K Ohgaki
Comparison fields: 5 of 78
  • Oncology 226
  • Immunology 125
  • Cancer Research 79
  • Biochemistry 20
  • Gastroenterology 18
Replace Toshimitsu Majima with:
Toshimitsu Majima Japan
Yongzeng Ding United States
Florian Corvinus Germany
Young‐Lan Park South Korea
Dina Kazanov Israel
Zunqi Hu China
Freya A. Goumas Germany
Sandra Huling United States
Gerhard Theyer Austria
Yukio Kurita Japan
K Ohgaki relative to Toshimitsu Majima Japan Toshimitsu Majima's profile →
Citations per field
00.5×
Toshimitsu Majima · 1×
Citations per year

Countries citing papers authored by K Ohgaki

Since Specialization
Citations

This map shows the geographic impact of K Ohgaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K Ohgaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K Ohgaki more than expected).

Fields of papers citing papers by K Ohgaki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K Ohgaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K Ohgaki. The network helps show where K Ohgaki may publish in the future.

Co-authorship network

The 25 scholars most cited alongside K Ohgaki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with K Ohgaki Line = papers co-authored together K Ohgaki links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1
[A case of HER2-positive metastatic breast cancer responding to trastuzumab plus gemcitabine combination therapy].
20081
2 20070
3 2004211
4 19947
5 19934
6 19935
7 199313
8 199227
9 19927
10 19915
11 19902
12 19909
13 199015
14
[Experimental study on the optimal treatment schedule for combination of BRM (immunostimulators, cultured killer cells or interleukin-2) and chemotherapy].
19901
15 19893
16 198911
17
[The therapeutic effects of OK-432 combined adoptive immunotherapy (AIT) against liver metastases of breast cancer].
19891
18
[A new anti-cancer agent K-18 (conjugate of human IgG and melphalan). (II). Its inhibitory effects on in vitro DNA synthesis of human tumor cells].
19860
19
[The oral administration of OK-432. The 5th report: the effects on the lymphoproliferative response and natural killer cell activity in mice with transplanted cecal tumors].
19852
20
[Tumor-specific cytotoxicity of tumor infiltrating lymphocytes (TIL) induced with TCGF in murine mammary carcinoma].
19844

About K Ohgaki

K Ohgaki is a scholar working on Immunology, Oncology and Biotechnology, having authored 55 papers that have together received 502 indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (13 papers), Immunotherapy and Immune Responses (12 papers), Cancer Immunotherapy and Biomarkers (10 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Cancer Research and Treatments (6 papers), Glycosylation and Glycoproteins Research (3 papers), Cancer, Stress, Anesthesia, and Immune Response (3 papers) and Cancer therapeutics and mechanisms (3 papers). The work is most often cited by research in Oncology (226 citations), Immunology (125 citations) and Cancer Research (79 citations). K Ohgaki has collaborated with scholars based in Japan, Switzerland and Greece. Frequent co-authors include Norimichi Kan, Takashi Inamoto, Kohei Murata, Satoshi Hirano, Hiroaki Ohigashi, Toyomasa Katagiri, Yoichi Furukawa, Tatsuhiko Tsunoda, Masaki Miyamoto and Yusuke Nakamura. Their work appears in journals such as Journal of Clinical Oncology, Journal of Cancer Research and Clinical Oncology, Cancer Immunology Immunotherapy, Surgery Today and Breast Cancer Research and Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026